Presentations & Publications
Access a wide range of resources that provide detailed information on our products, programs, and collaborations.
Guadecitabine (SGI-110) – Solid Tumors AML, MDS or CMML
2019
- ASH 2019: Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response
- 2019 ASH: Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study
- 2019 ASH: Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration
- 2019 ASH: Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles
- 2019 ASH: Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients
- 2019 EHA: RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)
- 2019 MDSF: Long Term Survival Results and Prognostic Factors Results of Higher Risk MDS and CMML treated with guadecitabine
2017
- 2017 ASH: Predictors of Response and Survival in 206 AML Patients Treated with Guadecitabine in a Phase 2 Study
- 2017 ESH-AML: LINE-1 and P15 Demethylation May Predict Response to Guadecitabine
- 2017 ACCP: Population Pharmacokinetics Analysis for Guadecitabine (SGI-110) and Decitabine after Subcutaneous Dosing with SGI-110 in Patients with Relapsed/Refractory AML and MDS
- 2017 14th Intl. Symposium on MDS: Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naïve Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
2016
- 2016 ASH: Genetic Determinants of Response to Guadecitabine (SGI-110) in AML
- 2016 ASH: Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
- 2016 EHA: OS and subgroup results from randomized Phase 2 study of SGI-110 in previously treated MDS
- 2016 ASCO: Epigenetic resensitization in recurrent, platinum-resistant OC using SGI-110: Phase 2 results
- 2016 AACR: Immune checkpoint(s) expression in AML pts enrolled in phase 1-2 study with guadecitabine
- 2016 ESH-MDS: Results of a P2 study of SGI-110 in pts with r/r intermediate or high risk MDS or CMML
- 2016 TAT: Guadecitabine (SGI-110), a novel partner in immunotherapy
2015
- 2015 ASH:Comparison of Efficacy & Safety Results in 103 TN-AML Pts using 5 & 10 day regimens SGI-110
- 2015_ESH-AML: Baseline biomarkers and DNA demethylation correlate w. clinical responses in SGI-110
- 2015 ASH: Correlations Between Biomarkers and Clinical Responses in Phase 1/2 Study of Guadecitabine
- 2015 EHA: Late response & OS long term follow up of randomized P2 Study of SGI-110 in elderly AML
- 2015_ESH-AML: Baseline biomarkers and DNA demethylation correlate w. clinical responses in SGI-110
- 2015 ASCO: Epigenome and Genome Alterations in Platinum Resistant Ovarian Cancer
- 2015: AACR First Results of a 10-Day Regimen of SGI-110 in Previously Untreated Elderly AML
- 2015: AACR PD and PK Results of SGI-110 in Patients with HCC after Progression on Sorafenib
- 2015 AACR Novel Combination Therapy of SGI-110 and BMN-673 for BRCA-Proficient Ovarian Cancer
- 2015 AACR: Determinants of hypomethylation and clinical response in r/r AML pts treated with SGI-110
- 2015 Keystone Conf: DNA Methylome Alterations in Platinum Resistant Ovarian Cancer Tumors
- 2015 ASCPT: Systems Pharmacology Modeling of Decitabine and SGI-110
2014
- 2014: ASH First clinical results of P2 study of SGI-110 in intermediate or high risk MDS or CMML
- 2014:ASH Identification of Methylation Biomarkers to Predict Clinical Response to SGI-110 in AML pts
- 2014 EORTC: Epigenetic immunomodulation by SGI-110 combined with immune check-point blockade
- 2014: ESMO Comparison of Efficacy & Safety 5-day & 10-day schedules of SGI-110 treatment of r/r AML
- 2014 EHA: Results of a Randomized Multicenter Phase 2 Study of a 5-day Regimen of SGI-110
- 2014 ASCO: First results of a Phase 2 study using a 10-day SC regimen of the HMA SGI-110 for r/r AML
- 2014 AACR: SGI-110 SQ provides superior disposition profile for active metabolite decitabine
- 2014 AACR: Clinical epigenetic resensitization of platinum-resistant recurrent ovarian cancer
- 2014 Clinical Epigenetics International Meeting. Identification of Novel Biomarker Candidates
- 2014 AACR: SGI-110 DNA HMA SGI-110 reverses Platinum resistance of ovarian cancer models
2013
- 2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML
- 2013 ASH: Determinants of Demethylation and Clinical Response in AML patients treated with SGI-110
- 2013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts
- 2013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating
- 2013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11
- 2013 AACR: SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells
- 2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade
- 2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine
- 2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
- 2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
- 2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11
- 2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT
2012
- 2012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110
- 2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines
- 2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer
- 2012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent
- 2012 AACR: Scale up & development of a process for a low volume subcutaneous formulation of SGI-110
2010
- 2010 AACR_Immunomodulatory Activity of SGI-110
- 2010 AACR J_S110 is Effective DNA Methylation Inhibitor In vivo and Reduces Tumor Growth
- 2010 ASH_SGI-110 Preclinical, PK, DNA Methylation of Low Vol Subcutaneous Formulation
- 2010 EORTC_Immunomodulatory activity of SGI-110
- 2010 isBTC_Immunomodulatory activity of SGI-110
Presentations & Publications Archive
© Astex Pharmaceuticals
All rights reserved
